ME - 23andMe Holding Co.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Sunnyvale,
United States
Type: Equity
ME price evolution
ME
| (in millions $) | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $256.39 | $314.35 | ||
| Short term investments | ||||
| Net receivables | $18.15 | $1.5 | $4.12 | |
| Inventory | $15.67 | $14.98 | $11.81 | |
| Total current assets | $309.96 | $298 | $360.28 | |
| Long term investments | ||||
| Property, plant & equipment | $81.01 | $85.35 | $90.03 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $608.21 | $801.23 | $871.2 | |
| Current liabilities | ||||
| Accounts payable | $13.17 | $8.55 | $12.75 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $144.14 | $101.6 | $118.91 | |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $231.02 | $175.98 | $195.71 | |
| Shareholders' equity | ||||
| Retained earnings | -$1964.25 | -$1686.28 | -$1611.01 | |
| Other shareholder equity | -$0.95 | |||
| Total shareholder equity | ||||
| (in millions $) | 1 May 2023 | 1 May 2022 | 1 May 2021 | 1 May 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $386.85 | $553.18 | $282.49 | $207.94 |
| Short term investments | ||||
| Net receivables | $1.9 | $3.38 | $2.48 | $6.39 |
| Inventory | $10.25 | $10.79 | $6.24 | $14.12 |
| Total current assets | $424.99 | $601.79 | $313.57 | $252.52 |
| Long term investments | ||||
| Property, plant & equipment | $94.69 | $105.43 | $124.01 | $138.49 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $942.6 | $1152.07 | $452.1 | $404.63 |
| Current liabilities | ||||
| Accounts payable | $12.92 | $37.93 | $12.27 | $13.09 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $149.42 | $153.24 | $121.62 | $139.45 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $228.66 | $236.41 | $210.37 | $270.43 |
| Shareholders' equity | ||||
| Retained earnings | -$1506.38 | -$1194.73 | -$977.24 | -$793.62 |
| Other shareholder equity | -$0.62 | $0.18 | ||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 29 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $100.56 | |||
| Cost of revenue | ||||
| Gross Profit | $47.06 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $116.51 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.03 | |||
| Interest expense | $0.06 | |||
| Net income | ||||
| Net income | -$69.54 | |||
| Income (for common shares) | ||||
| (in millions $) | 1 May 2022 | 1 May 2021 | 1 May 2020 | 1 May 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $271.89 | $243.92 | $305.46 | $440.9 |
| Cost of revenue | ||||
| Gross Profit | $132.94 | $117.01 | $137.43 | $192.89 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $387.1 | $302.21 | $351.19 | $381.67 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$3.48 | |||
| Interest expense | $0.28 | $1.58 | $7.58 | $5.25 |
| Net income | ||||
| Net income | -$217.49 | -$183.62 | -$250.86 | -$183.53 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$4.95 | -$2.9 | -$108.14 | -$104.94 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $7.18 | $1.53 | $546 | $540.48 |
| Effect of exchange rate | $1.45 | $0.62 | -$0.15 | |
| Change in cash and equivalents | -$142.29 | -$73.78 | $270.88 | $303.92 |
| (in millions $) | 1 May 2022 | 1 May 2021 | 1 May 2020 | 1 May 2019 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$108.14 | -$6.54 | -$72.82 | -$27.84 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $546 | $155.34 | $8.83 | $344.45 |
| Effect of exchange rate | -$0.15 | |||
| Change in cash and equivalents | $270.88 | $74.55 | -$249.76 | $218.49 |
News
|
23andMe Jumps as CEO Floats Taking DNA Tester Private
Bloomberg via Yahoo Finance
18 Apr 2024
|
|
23andMe CEO Anne Wojcicki eyes taking DNA-testing company private
Seeking Alpha
18 Apr 2024
|
|
23andMe CEO reveals take-private plan
Proactive Investors
18 Apr 2024
|
|
23andMe founder Anne Wojcicki wants to take the company private - San Francisco Business Times
The Business Journals
18 Apr 2024
|
|
23andMe May Disappear as Public Stock
247wallst.com
18 Apr 2024
|
|
23andMe shares rise on potential private takeover By Investing.com
Investing.com
18 Apr 2024
|
|
23andMe stock jumps as CEO plans to take company private By Investing.com
Investing.com
18 Apr 2024
|
|
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks...
Benzinga
8 Feb 2024
|
|
Dow Tumbles Over 100 Points; US Initial Jobless Claims Fall Last Week - Digital Turbine...
Benzinga
8 Feb 2024
|
|
Earnings call: 23andMe reports strategic progress amid revenue decline
Investing.com
8 Feb 2024
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |